More Stories

Informist, Friday, Mar. 27, 2026

 

MUMBAI – The Nifty Pharma index is seen moving in a range next week amid weak investor sentiment. It is expected to continue its run as a defensive sector amid heightened volatility, analysts said. While analysts still see decent sales prospects from the new generic weight loss drugs, the competitive pricing among pharma majors may limit market share gains. Indian pharmaceutical market leaders are expected to have an edge on other players in the weight-loss segment due to their expertise in distribution, marketing, and outreach. 

 

The race to gain initial leadership in generic semaglutide sales has picked up pace significantly as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and several other companies launched their generic semaglutide injections in India earlier this week. Other smaller companies, such as Glenmark Pharmaceuticals, Zydus Lifesciences, Alkem Laboratories, and Torrent Pharmaceuticals have also entered the fray.

 

"Initially, we were expecting a 50–70% discount to branded (Semaglutide-based) drugs, but seeing the intial pricing from Natco Pharma and Alkem Labs, maybe further price cuts are on the way," an analyst at a domestic brokerage said. "We are doubtful that domestic players will be able to gain a significant market share (in GLP-1 category) amid dominance by foreign players and low prices."  

 

The analyst added that this price cut would not be unprecedented either, as generic forms of semaglutide in China reached as much as 90% discount levels. Companies such as Sun Pharmaceutical are poised to benefit the most in this slim-margin competition owing to their mature distribution chains and experienced medical sales representatives. "We are waiting for generic semaglutide sales figures before building numbers and revenue contribution projections," the analyst added.       

 

There are other concerns for players involved in the weight loss drugs market apart from increased competition. The Drugs Controller General of India has intensified its regulatory surveillance against the unauthorised sale and promotion of the glucagon-like-peptide-1 drugs to curb potential malpractice across the drug supply chain and prevent unauthorised sales and use of drugs. 

 

The outcome of diplomatic talks between the US and Iran will determine the risk-taking appetite among investors in the near term, and an extension of hostilities in West Asia will likely scar pharmaceutical stocks as well, analysts said. Pharma companies are not substantially exposed to the disruption in West Asia, but are susceptible to its second-order impacts of higher inflation and shipping bottlenecks.

 

"The Nifty Pharma index has been consolidating in a range (21000–23600 points) for the last one year," Vipin Kumaar, senior technical analyst at Globe Capital Markets, said. He added that a rise or fall from this range is essential for Nifty Pharma's direction in the short term. The index will find immediate support at 21900 points for the coming week and resistances are placed around 23400–23600 levels, he said. This week, the index ended slightly higher in a weak market at 22565.60 points. 

 

TOP HEADLINES

 

* Shreehas Pradeep Tambe to succeed Siddharth Mittal as Biocon's MD, CEO
* IPO Alert:Sai Parenteral's issue sees some traction on day 2, subscribed 41%
* HC asks Dr Reddy's to halt sale of diabetes drug Olymviq on Novo Nordisk plea
* Aurobindo Pharma arm inks marketing, distribution pact for biosimilars in EU
* SC OKs Maharashtra's withdrawal of electricity duty relief to RIL, others
* Lupin gets US FDA's tentative approval for pitolisant tablets
* IPO Alert:Sai Parenteral's issue subscribed just 4% on day 1; QIBs stay away
* Govt intensifies scrutiny on GLP-1 drugs amid concerns of unauthorised sales
* SC directs release of INR 51 bln deposited in Sandesara case to banks in 1 wk
* Dr Reddy's, Sun Pharma, others launch semaglutide injections in India
* Alkem Labs gets compliance certificate for Daman unit from Malta govt body
* Divi's Labs gets draft order from income tax dept to pay INR 5.71 bln
* Eris Life launches Semaglutide shots under 'SUNDAE' brand in India

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	26,135.00	(-)2.20	26,875.00	25,495.00
Alkem Laboratories	5,344.50	1.70	5,501.50	5,180.50
Aurobindo Pharma	1,314.20	1.80	1,343.40	1,281.40
Biocon	370.10	(-)2.90	383.20	361.70
Cipla	1,242.30	(-)1.10	1,262.00	1,216.60
Divi's Laboratories	5,997.50	(-)1.70	6,122.50	5,872.50
Dr Reddy's Laboratories	1,281.70	(-)1.30	1,312.30	1,262.90
Gland Pharma	1,724.10	6.00	1,841.30	1,621.50
GlaxoSmithKline Pharmaceuticals	2,259.50	(-)5.30	2,357.00	2,206.40
Glenmark Pharmaceuticals	2,170.50	(-)0.40	2,210.30	2,126.70
Granules India	624.35	5.70	638.60	611.90
Ipca Laboratories	1,586.00	2.70	1,655.90	1,513.30
Laurus Labs	1,008.80	2.20	1,030.60	989.60
Lupin	2334.80	0.50	2388.40	2,296.60
Natco Pharma	978.70	2.00	998.90	944.90
Pfizer	4,692.00	(-)1.70	4,822.00	4,580.00
Sanofi India	3,190.90	(-)5.80	3,403.60	3,053.60
Sun Pharmaceutical Industries	1,793.60	0.90	1,833.20	1,765.20
Torrent Pharmaceuticals	4,265.60	(-)0.10	4,363.70	4,203.70
Zydus Lifesciences	896.70	0.70	916.80	884.00
Index	Levels
Nifty Pharma	22565.60	0.10	22876.90	22328.40
Nifty 50	22819.60	(-)1.30	23318.30	22555.20
S&P BSE Sensex	73583.22	(-)1.30	75378.00	72637.00

 

 

End

 

Reported by Eshitva Prakash

Edited by Vandana Hingorani

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.